All the news Showing 6 of 6 articles from: CROI 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment outcomes HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy Liz Highleyman / 23 April 2015 Direct-acting antiviral regimens containing sofosbuvir (Sovaldi) and the drugs in Viekirax/Exviera were highly effective regardless of how soon hepatitis C viral load became undetectable after starting treatment, according to research presented at the recent ... Transmission and prevention Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR Michael Carter / 18 March 2015 Rates of hepatitis C virus (HCV) reoccurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI ... Treatment outcomes Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir Liz Highleyman / 18 March 2015 Almost all patients with hepatitis C virus alone or HIV/HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA ... Prognosis and disease progression Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US Liz Highleyman / 05 March 2015 The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced fibrosis or cirrhosis and therefore being at ... Deciding when and how to treat HCV Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... Treatment for people living with HIV and HCV Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection Liz Highleyman / 04 March 2015 A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis C for more than 95% of ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive